Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

656 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).
Boada M, Neve A, Das B, Wojtowicz J, Huang Z, Bullain S, Watkin M, Lott D, Bittner T, Delmar P, Klein G, Hofmann C, Kerchner GA, Smith J, Baudler M, Fontoura P, Doody RS. Boada M, et al. Among authors: hofmann c. J Alzheimers Dis. 2024 Dec 16:13872877241303644. doi: 10.1177/13872877241303644. Online ahead of print. J Alzheimers Dis. 2024. PMID: 39686620
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P; SCarlet RoAD Investigators. Ostrowitzki S, et al. Among authors: hofmann c. Alzheimers Res Ther. 2017 Dec 8;9(1):95. doi: 10.1186/s13195-017-0318-y. Alzheimers Res Ther. 2017. PMID: 29221491 Free PMC article. Clinical Trial.
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
Klein G, Delmar P, Voyle N, Rehal S, Hofmann C, Abi-Saab D, Andjelkovic M, Ristic S, Wang G, Bateman R, Kerchner GA, Baudler M, Fontoura P, Doody R. Klein G, et al. Among authors: hofmann c. Alzheimers Res Ther. 2019 Dec 12;11(1):101. doi: 10.1186/s13195-019-0559-z. Alzheimers Res Ther. 2019. PMID: 31831056 Free PMC article.
At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.
Boess FG, Scelsi MA, Grimmer T, Perry RJ, Tonietto M, Klein G, Hofmann C, Salami M, Wojtowicz J, Lansdall CJ, Lane C, Kerchner GA, Smith J, Doody RS. Boess FG, et al. Among authors: hofmann c. J Prev Alzheimers Dis. 2024;11(3):537-548. doi: 10.14283/jpad.2024.60. J Prev Alzheimers Dis. 2024. PMID: 38706270 Clinical Trial.
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).
Neve A, Das B, Wojtowicz J, Huang Z, Bullain S, Watkin M, Lott D, Bittner T, Delmar P, Klein G, Hofmann C, Kerchner GA, Smith J, Baudler M, Fontoura P, Doody RS. Neve A, et al. Among authors: hofmann c. J Alzheimers Dis. 2024;101(1):353-367. doi: 10.3233/JAD-240221. J Alzheimers Dis. 2024. PMID: 39177596 Free PMC article. Clinical Trial.
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P; SCarlet RoAD Investigators. Ostrowitzki S, et al. Among authors: hofmann c. Alzheimers Res Ther. 2018 Sep 27;10(1):99. doi: 10.1186/s13195-018-0409-4. Alzheimers Res Ther. 2018. PMID: 30261916 Free PMC article.
In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.
Aldea R, Grimm HP, Gieschke R, Hofmann C, Lott D, Bullain S, Delmar P, Klein G, Lyons M, Piazza F, Carare RO, Mazer NA. Aldea R, et al. Among authors: hofmann c. Alzheimers Dement (N Y). 2022 Jun 6;8(1):e12306. doi: 10.1002/trc2.12306. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35676943 Free PMC article.
Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model).
Mazer NA, Hofmann C, Lott D, Gieschke R, Klein G, Boess F, Grimm HP, Kerchner GA, Baudler-Klein M, Smith J, Doody RS; Alzheimer's Disease Neuroimaging Initiative. Mazer NA, et al. Among authors: hofmann c. Alzheimers Dement. 2023 Jun;19(6):2287-2297. doi: 10.1002/alz.12877. Epub 2022 Dec 1. Alzheimers Dement. 2023. PMID: 36454709
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Wang G, Li Y, Xiong C, McDade E, Clifford DB, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Libre-Guerra JJ, McCullough A, Joseph-Mathurin N, Chen CD, Mummery C, Wendelberger BA, Gauthier S, Masellis M, Holdridge KC, Yaari R, Chatterjee S, Sims J, Delmar P, Kerchner GA, Bittner T, Hofmann C, Bateman RJ; DIAN‐TU Study Team. Wang G, et al. Among authors: hofmann c. Alzheimers Dement (Amst). 2022 Nov 3;14(1):e12367. doi: 10.1002/dad2.12367. eCollection 2022. Alzheimers Dement (Amst). 2022. PMID: 36348972 Free PMC article.
656 results